Audited Financial Results for the quarter and Year ended on March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals posted FY25 standalone revenue from operations of Rs. 30,413 lakhs (vs Rs. 25,798 lakhs in FY24, up ~17.9%) and standalone net profit of Rs. 2,645 lakhs (vs Rs. 2,259 lakhs, up ~17.1%), with EPS at Rs. 40.36. On a consolidated basis, revenue grew ~30% to Rs. 34,038 lakhs, but the company swung to a consolidated net loss of Rs. 4,368 lakhs (vs profit of Rs. 1,051 lakhs) and reported negative operating cash flow of Rs. (2,725) lakhs. Consolidated EBITDA margin excluding other income collapsed from 10.37% to 0.79%, primarily due to losses at newly acquired subsidiaries. The board recommended a final dividend of Rs. 1 per share (10%) and approved acquisitions of 100% stake in Varenyam Healthcare and 40% in Varenyam Biolifesciences, along with a fresh equity issuance of 7.04 lakh shares at Rs. 1,356.40 each. Statutory auditors Shah Mehta & Bakshi issued an unmodified opinion on both standalone and consolidated results.
Standalone numbers remain healthy with steady growth and dividend, but the consolidated picture flags concerns: subsidiary-level losses dragged the group into a net loss despite strong top-line growth, and operating cash flow turned negative. Shareholders should watch the performance of newly acquired subsidiaries (Innoxel, Varenyam) and goodwill of Rs. 52.1 crore, which could weigh on consolidated profitability.